1. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: Evolving concepts of pathogenesis and management. Arthritis Res Ther 2010;12:213.
2. Nannini C, Medina-Velasquez YF, Achenbach SJ, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: A population-based study. Arthritis care & research 2013;65:1243-50.
3. Raimundo K, Solomon JJ, Olson AL, et al. Rheumatoid arthritis-interstitial lung disease in the united states: Prevalence, incidence, and healthcare costs and mortality. J Rheumatol 2019;46:360-369.
4. Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013;12:1076-84.
5. Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013;2013:759760.
6. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;4:443-8. (In eng).
7. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality. Annals of the rheumatic diseases 2017;76:1700-1706.
8. Kass DJ, Nouraie M, Glassberg MK, et al. Comparative profiling of serum protein biomarkers in rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Arthritis Rheumatol 2020;72:409-419.
9. Chen J, Doyle TJ, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2015;67:28-38.
10. Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 2015;191:1403-12.
11. Amigues I, Ramadurai D, Swigris JJ. Current perspectives on emerging biomarkers for rheumatoid arthritis-associated interstitial lung disease. Open Access Rheumatol 2019;11:229-235.
12. Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum kl-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 2019;21:58.
13. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014;19:493-500.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: The ucsd shortness of breath questionnaire. University of california, san diego. Chest 1998;113:619-24.
16. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906.
17. Washko GR, Lynch DA, Matsuoka S, et al. Identification of early interstitial lung disease in smokers from the copdgene study. Acad Radiol 2010;17:48-53.
18. Flaherty KR, Brown KK, Wells AU, et al. Design of the pf-ild trial: A double-blind, randomised, placebo-controlled phase iii trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017;4:e000212.
19. Yamakawa H, Kitamura H, Takemura T, et al. Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. Respirology 2018;23:1032-1040.
20. Rosas IO, Richards TJ, Konishi K, et al. Mmp1 and mmp7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. Plos Med 2008;5:623-633. (In English).
21. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-jo-1 antibody-positive interstitial lung disease. Arthritis Rheum-Us 2009;60:2183-2192. (In English).
22. Yamakawa H, Sato S, Nishizawa T, et al. Impact of radiological honeycombing in rheumatoid arthritis-associated interstitial lung disease. BMC Pulm Med 2020;20:25.
23. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum 2010;62:1583-91.
24. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: Results from an inception cohort. Rheumatology (Oxford) 2010;49:1483-9.
25. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2017;36:817-823.
26. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (ccp2) autoantibodies and extra-articular manifestations in greek patients with rheumatoid arthritis. Clin Rheumatol 2008;27:511-3.
27. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics--a large multicentre uk study. Rheumatology (Oxford) 2014;53:1676-82.
28. Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated lymphoid tissue: Taming inflammation in the lung. Front Immunol 2016;7:258.
29. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 2010;12:363-9.
30. Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol 2018;30:72-78.
31. Kim EJ, Collard HR, King TE, Jr. Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. Chest 2009;136:1397-1405.
32. Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified hrct classification of idiopathic pulmonary fibrosis according to the 2018 ats/ers/jrs/alat criteria. J Thorac Dis 2019;11:5247-5257.
33. Giles JT, Darrah E, Danoff S, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One 2014;9:e98794.
34. Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of interstitial lung disease in systemic sclerosis: The importance of pneumoproteins krebs von den lungen 6 and ccl18. Arthritis Rheumatol 2019;71:2059-2067.